Astellas sells its global dermatology business to Leo Pharma for Euros 675 million, the sale includes Protopic (except in Japan)

Astellas Pharma Inc. have announced that Astellas and LEO Pharma A/S entered into an Asset Purchase Agreement, under which Astellas will transfer its global dermatology business to LEO Pharma for � 675 million. Under the terms of the agreement, the assets and associated responsibilities relating to Astellas� global portfolio of dermatology products including Protopic (except for Protopic in Japan now marketed there by Maruho Co.), treatment for atopic dermatitis, and other products for the treatments of acne and skin infections, predominantly sold in the EMEA region, will be transferred to LEO Pharma. The closing of this transaction is anticipated in the first quarter of 2016. Following the closing, Astellas and LEO Pharma will work closely together to ensure a smooth and effective transition of the products and business to LEO Pharma.